RxDoctor Payments Data

Richard Phinney, MD

Hematology & Oncology · Toledo, OHNPI 1215192703

Payments from drug & device makers

$12,507in general payments, 2019–2025

Across 60 payments — averaging $208.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$6K
  • Daiichi Sankyo Inc.$2K
  • Pfizer$1K
  • Incyte Corporation$1K
  • Geron Corporation$795
  • AstraZeneca$216
  • plus $1K from 23 others

What the payments were for

  • Consulting fees$9,39675%
  • Speaking & faculty fees$1,20010%
  • Food & beverage$1,68113%
  • Education$2302%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,507 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$4,109,483
Medicare patients
811
Services billed
239,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate70$1,018,398
IbrancePalbociclib57$874,144
ImbruvicaIbrutinib25$440,925
VerzenioAbemaciclib27$411,198
CabometyxCabozantinib S-Malate12$301,311
BrukinsaZanubrutinib16$246,941
MektoviBinimetinib12$182,058
TagrissoOsimertinib Mesylate11$173,917
BraftoviEncorafenib12$164,415
ProcritEpoetin Alfa26$90,579
EliquisApixaban64$48,279
Abiraterone Acetate40$43,601
XareltoRivaroxaban35$21,140
Imatinib Mesylate35$13,300
Exemestane70$7,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$216$1,192,31581 claims
PfizerIbrance, Eliquis$1,215$922,424121 claims
Lilly USA, LLCVerzenio$13$411,19827 claims
Exelixis Inc.Cabometyx$12$301,31112 claims
Johnson & JohnsonProcrit, Xarelto$178$111,71861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →